DR. SHARON E. SOULE, M.D.
Osteopathic Medicine at Arkansas St, Lawrence, KS

License number
Kansas 0430104
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
330 Arkansas St SUITE 105, Lawrence, KS 66044
Phone
(785) 840-2800
(785) 840-2813 (Fax)

Personal information

See more information about SHARON E. SOULE at radaris.com
Name
Address
Phone
Sharon E Soule
330 Arkansas St, Laurence, KS 66044
(785) 505-2800
(785) 840-2800
Sharon E Soule, age 54
22010 53Rd St, Shawnee, KS 66226

Professional information

See more information about SHARON E. SOULE at trustoria.com
Sharon E Soule Photo 1
Dr. Sharon E Soule, Lawrence KS - MD (Doctor of Medicine)

Dr. Sharon E Soule, Lawrence KS - MD (Doctor of Medicine)

Specialties:
Hematology, Medical Oncology, Oncology
Address:
Lawrence Memorial Hosp ONC Ctr
330 Arkansas St SUITE 105, Lawrence 66044
(785) 505-2800 (Phone)
Certifications:
Hematology, 2003, Internal Medicine, 1999, Medical Oncology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Lawrence Memorial Hosp ONC Ctr
330 Arkansas St SUITE 105, Lawrence 66044
Lawrence Memorial Hospital
325 Maine St, Lawrence 66044
Education:
Medical School
University of Kansas / School of Medicine
Graduated: 1996
University Of Iowa Hospitals & Clinics
Indiana U


Sharon Elizabeth Soule Photo 2
Sharon Elizabeth Soule, Laurence KS

Sharon Elizabeth Soule, Laurence KS

Specialties:
Internal Medicine, Hematology & Oncology, Hematology, Medical Oncology
Work:
Lawrence Memorial Hospital
330 Arkansas St, Laurence, KS 66044
Education:
University of Kansas(1996)


Sharon Soule Photo 3
Gene Expression Markers For Predicting Response To Chemotherapy

Gene Expression Markers For Predicting Response To Chemotherapy

US Patent:
2005006, Mar 24, 2005
Filed:
May 24, 2004
Appl. No.:
10/852797
Inventors:
Joffre Baker - Montara CA, US
Kathy Miller - Zionville IN, US
Steven Shak - Hillsborough CA, US
George Sledge - Indianapolis IN, US
Sharon Soule - Lawrence KS, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
The invention provides sets of genes the expression of which predicts whether cancer patients are likely to have a beneficial treatment response to chemotherapy.